Center for Scientific Review; Notice of Closed Meetings, 49598 [2022-17301]
Download as PDF
<![CDATA[
49598
•
•
•
•
•
lotter on DSK11XQN23PROD with NOTICES1
•
Federal Register / Vol. 87, No. 154 / Thursday, August 11, 2022 / Notices
absence of nuclear localization of
XPA, AKAP12, and ATR–pS435 in
unirradiated cells transfected with
wild-type AKAP12 when the original
images showed positive signal
confocal microscopic images of
melanocytes in Figure 6H of Nucleic
Acids Res. 2016 by inserting blank
image panels to falsely represent the
absence of nuclear localization of
XPA, AKAP12, and ATR–pS435 in
unirradiated cells transfected with
mutant AKAP12 when the original
images showed positive signal
confocal microscopic images of
melanocytes in Figure 5A of Sci. Rep.
2017, by inserting blank image panels
in the top row, panels 1 and 4, to
falsely represent negative control
experiments, and the quantification
reported in Figure 5B that was
derived from falsified and/or
fabricated images in Figure 5A
confocal microscopic images of
melanocytes in Figure 1A, top row,
panels 1, 3, 5, and 7, of JBC 2018, by
inserting blank image panels to
represent negative control
experiments, and the quantification in
Figure 1B that was derived from
falsified and/or fabricated images in
Figure 1A
confocal microscopic images of
melanocytes in Figure 2B of JBC 2018
by using two different cells from the
same source image to falsely represent
different experimental results: a cell
for control conditions (top row, panel
1) and another cell to represent the
outcome of the treatment conditions
(top row, panel 8), as well as the
quantification reported in Figure 2C
that was derived from falsified and/or
fabricated images in Figure 2B
confocal microscopic images of
melanocytes in Figure 3D of JBC 2018
by using two different cell images
from the same source image to falsely
represent different experimental
results in: XPA–K215Q transfected
cells without forskolin (column 3,
rows 1 and 2 of lower right set of
panels) and XPA–K215Q transfected
cells with forskolin (column 4, rows
1 and 2 of lower right set of panels),
and the quantification reported in
Figure 3D that was derived from
falsified and/or fabricated images in
Figure 3D
confocal microscopic images of
melanocytes in JBC 2018 Figure 3D,
column 1, rows 1 and 2, of ‘‘XPA–
WT’’ set of panels, and in JBC 2018
Figure 3D, column 1, rows 1 and 2, of
‘‘XPA–K63Q’’ set of panels, by using
the same image field to represent UV
untreated cells ‘‘XPA–WT’’ and
‘‘XPA–K63Q’’ mutant, and the
quantification reported in Figure 3D
VerDate Sep<11>2014
17:49 Aug 10, 2022
Jkt 256001
that was derived from falsified and/or
fabricated images in Figure 3D
• confocal microscopic images of
melanocytes in Figure 2D (images in
column 1, rows 1 and 3) of Mol. Cell
2014 by reusing, manipulating, and
relabeling an image to falsely
represent the absence of [6–4]–PP in
both vehicle-treated cells and
forskolin-treated cells in negative
control experiments
• confocal microscopic images of
melanocytes in Figure 7C of Mol. Cell
2014 (and in Figure 2F of R01
CA207312–01, Figure 5A of R01
CA131075–06, and Figure 3B of R01
CA131075–06A1), by inserting blank
image panels to falsely represent
forskolin-treated cells and untreated
cells without UV exposure, and the
quantification reported in Figure 7C
and Figure 5A of R01 CA131075–06
that was derived from falsified and/or
fabricated images in Figure 7C
• confocal microscopic images of
melanocytes in Figure 4E of R01
CA131075–06A1 and Figure 4C of
R01 CA207312–01 by using cell
images from the same source
micrograph to falsely represent
cAMP-augmented interaction between
pS435–ATR and AKAP12
The following administrative actions
have been implemented:
(1) For a period of four (4) years,
beginning on July 18, 2022, Respondent
is debarred from participating in
‘‘covered transactions’’ as defined in 42
CFR 180.200 and procurement
transactions covered under the Federal
Acquisition Regulation (48 CFR chapter
1).
(2) Respondent is prohibited from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of four (4) years,
beginning on July 18, 2022.
(3) In accordance with 42 CFR
93.407(a)(1) and 93.411(b), HHS will
send to the journal Molecular Cell a
notice of ORI’s findings and the need for
retraction of Mol. Cell 2014 Jun
19;54(6):999–1011; doi: 10.1016/
j.molcel.2014.05.030.
Dated: August 8, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cell Biology
Integrated Review Group; Cellular Signaling
and Regulatory Systems Study Section.
Date: September 26–27, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; NIH
Research Enhancement Award (R15) in
Oncological Sciences.
Date: September 28, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Svetlana Kotliarova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
Bethesda, MD 20892, 301–594–7945,
kotliars@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
[FR Doc. 2022–17264 Filed 8–10–22; 8:45 am]
Dated: August 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4150–31–P
[FR Doc. 2022–17301 Filed 8–10–22; 8:45 am]
PO 00000
BILLING CODE 4140–01–P
Frm 00021
Fmt 4703
Sfmt 9990
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 87, Number 154 (Thursday, August 11, 2022)]
[Notices]
[Page 49598]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17301]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Cell Biology Integrated Review Group;
Cellular Signaling and Regulatory Systems Study Section.
Date: September 26-27, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189, MSC 7840, Bethesda, MD
20892, 301-435-1022, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; NIH Research Enhancement Award (R15) in Oncological Sciences.
Date: September 28, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Svetlana Kotliarova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214, Bethesda, MD 20892, 301-
594-7945, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: August 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-17301 Filed 8-10-22; 8:45 am]
BILLING CODE 4140-01-P
